10 Points On Dostarlimab, The Drug That 'Cured' Cancer During Trials

NDTV - 07 Jun 2022
The clinical trial comprised a group of 18 patients. All of them were battling rectal cancer at the Memorial Sloan Kettering Cancer Center in Manhattan, US. In ...

Dostarlimab Yields High cCR Rates and Organ Preservation in Early-Stage dMMR Tumors

OncLive - 09 May 2025
Dostarlimab Yields High cCR Rates and Organ Preservation in Early-Stage dMMR Tumors ...

Jemperli (dostarlimab), MAH: GlaxoSmithKline (Ireland) Limited

European Commission - 08 May 2025
Jemperli (dostarlimab), MAH: GlaxoSmithKline (Ireland) Limited ...

What is Dostarlimab?

Business Standard - 07 May 2025
What is Dostarlimab? ...

GSK's Jemperli (dostarlimab) plus chemotherapy approved in Singapore as the first frontline immuno-oncology treatment for dMMR/MSI-H primary advanced or recurrent endometrial cancer

PR Newswire - 07 Aug 2024
GSK's Jemperli (dostarlimab) plus chemotherapy approved in Singapore as the first frontline immuno-oncology treatment for dMMR/MSI-H primary advanced or recurrent endometrial cancer ...

FDA Grants Dostarlimab Breakthrough Therapy Designation in dMMR/MSI-H Rectal Cancer

Targeted Oncology - 16 Dec 2024
FDA Grants Dostarlimab Breakthrough Therapy Designation in dMMR/MSI-H Rectal Cancer ...

Dostarlimab Combo Earns Expanded European Approval in Endometrial Cancer

Cancer Network - 20 Jan 2025
Dostarlimab Combo Earns Expanded European Approval in Endometrial Cancer ...

A New Immune Treatment May Work Against Several Cancer Types

Time Magazine - 28 Apr 2025
A New Immune Treatment May Work Against Several Cancer Types ...

Immunotherapy helps certain cancer patients avoid surgery: ‘We hope this is the future’

CNN - 05 May 2025
Immunotherapy helps certain cancer patients avoid surgery: ‘We hope this is the future’ ...

Pipeline

GSK - 30 Apr 2025
Pipeline ...

CITRINO: phase 1 dose escalation study of anti-LAG-3 antibody encelimab alone or in combination with anti-PD-1 dostarlimab in patients with advanced/metastatic solid tumours

Nature - 27 Feb 2025
CITRINO: phase 1 dose escalation study of anti-LAG-3 antibody encelimab alone or in combination with anti-PD-1 dostarlimab in patients with advanced/metastatic solid tumours ...

Real-World Analysis Confirms Efficacy/Safety of Dostarlimab Plus Chemotherapy in Advanced Endometrial Cancer

OncLive - 17 Mar 2025
Real-World Analysis Confirms Efficacy/Safety of Dostarlimab Plus Chemotherapy in Advanced Endometrial Cancer ...

Real-World Data Support Dostarlimab Combo Benefit in RUBY Trial

Cancer Network - 20 Mar 2025
Real-World Data Support Dostarlimab Combo Benefit in RUBY Trial ...

Neoadjuvant Dostarlimab Eradicates Disease in 82% of Mismatch Repair–Deficient Solid Tumors

OncLive - 28 Apr 2025
Neoadjuvant Dostarlimab Eradicates Disease in 82% of Mismatch Repair–Deficient Solid Tumors ...

Dostarlimab/Chemo Improves Long-Term DOR in Advanced Endometrial Cancer

OncLive - 17 Mar 2025
Dostarlimab/Chemo Improves Long-Term DOR in Advanced Endometrial Cancer ...

Dostarlimab/Chemo Earns Expanded Canadian Approval in Primary Advanced, First Recurrent Endometrial Cancer

OncLive - 18 Apr 2025
Dostarlimab/Chemo Earns Expanded Canadian Approval in Primary Advanced, First Recurrent Endometrial Cancer ...

European Commission Approves Dostarlimab Plus Chemo for All Advanced/Recurrent Endometrial Cancer

OncLive - 20 Jan 2025
European Commission Approves Dostarlimab Plus Chemo for All Advanced/Recurrent Endometrial Cancer ...

Dr Mirza on Long-Term Response Data for Dostarlimab Plus Chemo in Advanced Endometrial Cancer

OncLive - 26 Mar 2025
Dr Mirza on Long-Term Response Data for Dostarlimab Plus Chemo in Advanced Endometrial Cancer ...

FDA Grants Breakthrough Therapy Designation to Dostarlimab for dMMR/MSI-H Rectal Cancer

OncLive - 18 Dec 2024
FDA Grants Breakthrough Therapy Designation to Dostarlimab for dMMR/MSI-H Rectal Cancer ...

Frontline Dostarlimab/Chemo Maintains Numerical OS Benefit in Advanced NSCLC

OncLive - 08 Nov 2024
Frontline Dostarlimab/Chemo Maintains Numerical OS Benefit in Advanced NSCLC ...

Dostarlimab